chrisvoncsefalvay/vaers-outcomes huggingface dataset:
acute parotitis; hurts to chew; Brain fog; brain issues; left side of jaw area is completely swollen/facial swelling; face turned red like sunburn; my body got dehydrated completely, same night was super dehydrated; This spontaneous case was reported by a consumer and describes the occurrence of DEHYDRATION (my body got dehydrated completely, same night was super dehydrated), ERYTHEMA (face turned red like sunburn), PAROTITIS (acute parotitis), SWELLING FACE (left side of jaw area is completely swollen/facial swelling) and MASTICATION DISORDER (hurts to chew) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033C2A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 19-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-May-2021, the patient experienced DEHYDRATION (my body got dehydrated completely, same night was super dehydrated). On 21-May-2021, the patient experienced ERYTHEMA (face turned red like sunburn). On 24-May-2021, the patient experienced SWELLING FACE (left side of jaw area is completely swollen/facial swelling). On an unknown date, the patient experienced PAROTITIS (acute parotitis), MASTICATION DISORDER (hurts to chew), FEELING ABNORMAL (Brain fog) and CEREBRAL DISORDER (brain issues). At the time of the report, DEHYDRATION (my body got dehydrated completely, same night was super dehydrated), ERYTHEMA (face turned red like sunburn), PAROTITIS (acute parotitis), MASTICATION DISORDER (hurts to chew) and CEREBRAL DISORDER (brain issues) outcome was unknown, SWELLING FACE (left side of jaw area is completely swollen/facial swelling) had resolved and FEELING ABNORMAL (Brain fog) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Computerised tomogram: acute parotitis (abnormal) acute parotitis.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication were provided  Treatment medication included antibiotic, anti-inflammatory for acute parotitis   Most recent FOLLOW-UP information incorporated above includes: On 30-Jun-2021: Follow-up received on 30-Jun-2021 included new event
Yesterday MA had a patient come in for his second Shingrix vaccine.  In his chart, the Private log for vaccines in the lab, and his receipt for the vaccine, MA wrote down and marked "Shingrix" everywhere. However, when MA went to get the vaccine ready, MA grabbed a Tdap vaccine and administered that to him instead of the Shingrix. Peer check and she as well, did not catch the wrong vaccine.  The tdap vaccine was also not from our private batch of vaccines, it  came from the 317 batch.  Said the tdap was fine for him to have in the end, and we did call the patient and i left a voicemail for him to return our call but i have not heard back from him. I did try calling agian this morning with no answer.   Patient came in today to receive shingrix vaccine on 6/30/22
3rd dose of Shingrix; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 74-year-old male patient who received Herpes zoster (Shingrix) (batch number X9KC7, expiry date 25-OCT-2024) for prophylaxis.   Previously administered products included Shingrix (1st and 2nd dose received on an unknown date).   On 10-JUL-2023, the patient received the 3rd dose of Shingrix. On 10-JUL-2023, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: 3rd dose of Shingrix). The outcome of the extra dose administered was unknown.   Additional Information: GSK receipt date: 10-JUL-2023 Pharmacist called to inform that earlier that day, a patient received a 3rd dose of Shingrix.  The Vaccine Administration Facility was the same as Primary Reporter. Consented to follow up.
Today the other part of my face, the right part is swollen, bigger.; The nerve on my back hurts, like spasm; I was having random joint pain, and in my index finger/The joint in my arms and shoulders and outside of hips hurt.; My right eye was swollen; Bone pain in my sacral area, like sharp stabbing pain which hurst the most; I was having random joint pain, and in my index finger; The nerve on my back hurts, like spasm.; My arm was sore later that night./was really sore/arm is still sore but not as bad; This spontaneous case was reported by a consumer and describes the occurrence of EYE SWELLING (My right eye was swollen), BONE PAIN (Bone pain in my sacral area, like sharp stabbing pain which hurst the most), PAIN IN EXTREMITY (I was having random joint pain, and in my index finger), NEURALGIA (The nerve on my back hurts, like spasm.) and SWELLING FACE (Today the other part of my face, the right part is swollen, bigger.) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 939901) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 18-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Sep-2021, the patient experienced VACCINATION SITE PAIN (My arm was sore later that night./was really sore/arm is still sore but not as bad). On 24-Sep-2021, the patient experienced EYE SWELLING (My right eye was swollen), BONE PAIN (Bone pain in my sacral area, like sharp stabbing pain which hurst the most), PAIN IN EXTREMITY (I was having random joint pain, and in my index finger), NEURALGIA (The nerve on my back hurts, like spasm.), MUSCLE SPASMS (The nerve on my back hurts, like spasm) and ARTHRALGIA (I was having random joint pain, and in my index finger/The joint in my arms and shoulders and outside of hips hurt.). On 03-Oct-2021, the patient experienced SWELLING FACE (Today the other part of my face, the right part is swollen, bigger.). The patient was treated with PARACETAMOL (TYLENOL) for Pain in arm, at an unspecified dose and frequency. At the time of the report, EYE SWELLING (My right eye was swollen), BONE PAIN (Bone pain in my sacral area, like sharp stabbing pain which hurst the most), PAIN IN EXTREMITY (I was having random joint pain, and in my index finger), NEURALGIA (The nerve on my back hurts, like spasm.), SWELLING FACE (Today the other part of my face, the right part is swollen, bigger.), MUSCLE SPASMS (The nerve on my back hurts, like spasm), VACCINATION SITE PAIN (My arm was sore later that night./was really sore/arm is still sore but not as bad) and ARTHRALGIA (I was having random joint pain, and in my index finger/The joint in my arms and shoulders and outside of hips hurt.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication details was reported.
Fever when waking up, 101F, slight headache, and aching arm. Took 2 TYLENOL went back to bed. Fever down by 12 noon. Took another does of TYLENOL at 1 pm, went back to bed. Recovered by 4 pm.
Adverse event occurred approximately 11-13 hours vaccination.  Moderate chills, turned into approximately 100 degree fever (felt like the fever is breaking), sweating, became dizzy, vision was spotty, and then fainted.  (Adverse event occurred after both doses. After receiving  1st dose (February 26) and 2nd dose (March 26).
No additional adverse effect reported; PNEUMOVAX23 underwent temperature excursions was administered; This spontaneous report has been received from a pharmacist referring to a currently 19 days old patient of unknown gender. Information about pertinent medical history, concomitant medication and drug reactions/allergies was not provided.  On an unknown date in September 2021, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) lot # T020639, for prophylaxis (strength, dose and route were not provided). The administered vaccine underwent temperature excursions (Product storage error). The storage temperature of the pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) was reported as below 36 degree Fahrenheit (34 degree Fahrenheit) for a time frame of 12 hours 57 minutes. There was no previous temperature excursion. No additional adverse effect reported.  This is one of two reports received from the same reporter. ; Sender's Comments:  US-009507513-2109USA007279:
Four hours after vaccination patient began vomiting, experienced headache, diffuse body aches, as well as diffuse itching of her skin.  She took Benadryl which reduced the itching, but did not resolve it.  The day after vaccination she continued to vomit as well as experience fatigue, diffuse bone and joint aching, as well as continued itching and headache.  Patient was seen in my office two days after vaccination and was still experiencing diffuse itching, as well as joint and bone aching and a headache.
During registration an error occurred in documenting pt, dob 12-21-06 registered as 11/21/06. This caused early administration of vaccines by 1 month. No adverse reactions occurred.
vaccine exposure during pregnancy; Initial information received on 02-Sep-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 34 years old female patient who was exposed to vaccine INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT]  in context of vaccine exposure during pregnancy.   Data regarding this pregnancy were received prospectively, i.e. before pregnancy outcome was known. The reported vaccine exposure during pregnancy occurred at 16 weeks of pregnancy and the patient was exposed to INFLUENZA QUADRIVAL A-B VACCINE at 16 weeks of pregnancy, during second pregnancy trimester for INFLUENZA QUADRIVAL A-B VACCINE.   The date of last menstrual period was reported as 20-May-2022. The estimated due date is 23-Feb-2023. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.    On 01-Sep-2022, the patient received a  dose of suspect INFLUENZA QUADRIVAL A-B VACCINE Suspension for injection (lot uT7682KA) via intramuscular route in the left deltoid for prophylactic vaccination.  On 01-SEP-2022 the patient reported a non-serious event vaccine exposure during pregnancy (exposure during pregnancy) following the administration of INFLUENZA QUADRIVAL A-B VACCINE.  Action taken: not applicable.  At time of reporting, the outcome was Unknown for the event exposure during pregnancy.  Additionally, at time of reporting, the pregnancy is still ongoing.
pt recv vax 9SEP96 & MAY97 pt devel a vesicular pustular varicella-type rash consisting of approx 50 lesions;
Well check up and shots at 12Noon-12:30. Pt mom called at 5pm baby cried x 2 hrs inconsolable wouldn't feed after shots.
mild rash on abdomen and back (bilateral), sides of torso and armpit (bilateral), left lower arm, inside of both thighs; This is a spontaneous report from a contactable consumer (patient). A 56-years-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: EM9809 and Expiry date was not reported), via an unspecified route of administration administered in Arm Left on 05Feb2021 11:00 (at the age of 56-years-old) as dose 1, single for COVID-19 immunization. Patient had no known allergies. Medical history included mycotic allergy, seasonal allergy and food allergy from an unknown date and unknown if ongoing Various environmental and food allergies: Mold, tree pollens, tomato, variety of beans. Concomitant medication(s) included fluvoxamine maleate (FLUVOXAMINE MALEATE) and trazodone (TRAZODONE), both taken for an unspecified indication, start and stop date were not reported.Patient did not receive any other vaccine in four weeks. The patient was not diagnosed with COVID-19 prior to vaccination. Post vaccination the patient tested negative for COVID 19. It was reported that on 13Feb2021 20:00, adverse event mild rash on abdomen and back(bilateral), sides of torso and armpit (bilateral), left lower arm, inside of both thighs.Patient did not received any treatment for the event. The patient underwent lab tests and procedures which included sars-cov-1 test with nasal swab was negative on 18Feb2021. The outcome of rash was recovered.   Follow-up attempts are completed. No further information is expected.
Vomited for several hours; This spontaneous case was reported by a consumer and describes the occurrence of VOMITING (Vomited for several hours) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VOMITING (Vomited for several hours). At the time of the report, VOMITING (Vomited for several hours) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant information use was not reported.  Treatment information was not provided.
vision issues; rash on their forearm/rash forehead/rash on their sculp/rash on their neck; headaches; This spontaneous case was reported by a consumer and describes the occurrence of VISUAL IMPAIRMENT (vision issues), RASH (rash on their forearm/rash forehead/rash on their sculp/rash on their neck) and HEADACHE (headaches) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included COVID-19 (had COVID before getting the vaccines).    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VISUAL IMPAIRMENT (vision issues), RASH (rash on their forearm/rash forehead/rash on their sculp/rash on their neck) and HEADACHE (headaches). At the time of the report, VISUAL IMPAIRMENT (vision issues), RASH (rash on their forearm/rash forehead/rash on their sculp/rash on their neck) and HEADACHE (headaches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications were not provided. No Treatment information was provided. The administration of the Moderna vaccine was before Jun-2021.
fever of 102 x 2 days; constant crying x 2 days; mom contacted MD;
Pt was confused, weak legs had fever, dehydrated, sweating, couldn't talk, MD Rx chemotherapy and LUPRON shots for Pt, possible flu, or infection
Vaccine administered after temperature excursion; This spontaneous report was received from a medical assistant regarding a 12-month old patient of unknown gender. The patient's pertinent medical history, concurrent condition, concomitant medications, drug reactions and allergies were not reported.   On 17-AUG-2020, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) (vaccination regimen, route of administration, and anatomical location were not reported; lot # S012037 was verified to be valid, expiration date reported as 17-APR-2021) as prophylaxis (product storage error).   It was reported that the vaccine was stored in temperature of 5 degrees Celsius (reported as 5c) for a time frame of 12 hours.  The previous temperature excursion was at 8.4 degrees Fahrenheit (8.4°F) for a time frame of 60 hours. The call was due to a data-logger.
COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Ulcerative colitis and Crohn's disease.    No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced COVID-19 (COVID-19). At the time of the report, COVID-19 (COVID-19) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  No treatment information was reported.  Company comment: This spontaneous case concerns an adult female patient of an unknown age, with no reported medical history, who experienced the unexpected non-serious AESI COVID-19 occurred on an unknown date in the context of receiving a dose of mRNA-1273 vaccine. Onset latency could not be determined as date of vaccine and event onset date were not provided. Clinical course and treatment details were not reported. The outcome of event was reported as resolved. On unknown date, patient received co-suspect Adalimumab for Crohn's disease and ulcerative colitis which could be a confounder. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns an adult female patient of an unknown age, with no reported medical history, who experienced the unexpected non-serious AESI COVID-19 occurred on an unknown date in the context of receiving a dose of mRNA-1273 vaccine. Onset latency could not be determined as date of vaccine and event onset date were not provided. Clinical course and treatment details were not reported. The outcome of event was reported as resolved. On unknown date, patient received co-suspect Adalimumab for Crohn's disease and ulcerative colitis which could be a confounder. The benefit-risk relationship of mRNA-1273 is not affected by this report.
Next day, in afternoon, started to feel bad. Blood pressure spiked. Regular BP is 125/80 and 4 reading checks were around 210/120. Took DIOVAN and after 6 hours BP lowered to down to 145. Next day went down further to normal. No rash. On Wednesday, stomach problems started. Couldn't do bowel movement. Finally got better today but still not normal. -Bad headache on Wednesday took TYLENOL.
Pt recv vax 27Mar97 & 28May97 vax 1st & 2nd dose varicella virus vax live SC. 31Dec97 Varicella antibody test revealed lack of seroconversion. (0.3)
After 2 months, pain at injection site reappeared (had gone away a few days after vaccine and then reappeared 2 months later)
Moderna 0.25 ml administered for a Moderna primary series. The correct dose that should have been administered was 0.5 ml. No direct harm to the patient noted. Patient contacted and asked to return to receive an additional 0.25 ml if he could return same day or 0.5 ml if he will need to return on a different day. per the guidelines. Patient voiced understanding.
pt called & stated has soreness in lt arm for 1 to 1 1/2 wk p/vax & then went away; later pt exp severe pain in lt shoulder & deltoid area w/pain not relieved w/med & that persists even now;
No adverse events reported by the patient.  However, this was 3rd time the patient received Shingrix injection, instead of just 2 doses.  Previous doses were administered on 05/28/18, 07/31/18.  Third dose was given 1/8/19.
covid positive test; Lost taste; Weakness; cough; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (covid positive test), COUGH (cough), ASTHENIA (Weakness) and AGEUSIA (Lost taste) in a 76-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     The patient's past medical history included Prediabetes since an unknown date and Guillain Barre syndrome (GBS 35 years ago).    On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Jan-2021, the patient experienced COUGH (cough). On 20-Jan-2021, the patient experienced ASTHENIA (Weakness). On 24-Jan-2021, the patient experienced SARS-COV-2 TEST POSITIVE (covid positive test) and AGEUSIA (Lost taste). The patient was treated with BENZONATATE (oral) for Adverse event, at a dose of 100 mg. At the time of the report, SARS-COV-2 TEST POSITIVE (covid positive test), COUGH (cough), ASTHENIA (Weakness) and AGEUSIA (Lost taste) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 24-Jan-2021, SARS-CoV-2 test: Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant Concomitant medications were reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 22-Feb-2021 and was forwarded to Moderna on 23-Feb-2021.    This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (covid positive test), COUGH (cough), ASTHENIA (Weakness) and AGEUSIA (Lost taste) in a 76-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     The patient's past medical history included Prediabetes since an unknown date and Guillain Barre syndrome (GBS 35 years ago).    On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Jan-2021, the patient experienced COUGH (cough). On 20-Jan-2021, the patient experienced ASTHENIA (Weakness). On 24-Jan-2021, the patient experienced SARS-COV-2 TEST POSITIVE (covid positive test) and AGEUSIA (Lost taste). The patient was treated with BENZONATATE (oral) for Adverse event, at a dose of 100 mg. At the time of the report, SARS-COV-2 TEST POSITIVE (covid positive test), COUGH (cough), ASTHENIA (Weakness) and AGEUSIA (Lost taste) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 24-Jan-2021, SARS-CoV-2 test: Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant Concomitant medications were reported.
About 8pm same day as vaccine started exp chills,fever and the thumb right hand turned blackish purple in color. The discoloration continued overnight contacted my physician the next day. I went into the office she did blood work for any possible blood clots. It took 5 days for the thumb on  my right hand to come back to normal color.
This spontaneous report was received from a certified medical assistant concerning an approximately 3 month old female patient with no pertinent medical history and no drug reactions or allergies. On 09-NOV-2013, the patient was vaccinated with a dose of ROTATEQ (lot number was reported as J002785, expiry date and dose unspecified), orally. There was no concomitant therapy. On 08-NOV-2013, shortly after vaccination, the patient vomited. No treatment was given and no lab tests were performed. The outcome of the event was unknown. The relatedness for the event was unknown for ROTATEQ. Additional information has been requested.
pt presented 6 days p/vax w/possible chickenpox rash;returned on 29JUL97 12 days p/vax & was cleared;31JUL97 pt had weakness on rt side;blurred vision;adm to hosp w/encephalitis poss r/t to vax;
pt recv vax MAY95 & 2 wk later found out was pregnant via pos urine HCG test; pregnancy was terminated @ wk 9 by D&C D/T declining HCG levels
Moderna booster administered 11/16/21, vaccine expired 11/7/21.  Mistakenly read the expiration date as 11/17/21.  No adverse event or outcome to recipient.
pt devel redness, swelling, itching, & pain in arm p/pnu-immune 23 inject; pt never had a pneumococcal vax; resolved w/no sequelae;